- Home
- VTYX vs BFIN Comparison
VTYX vs BFIN Comparison
Compare VTYX & BFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- BFIN
- Stock Information
- Founded
- VTYX 2018
- BFIN 1924
- Country
- VTYX United States
- BFIN United States
- Employees
- VTYX N/A
- BFIN N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- BFIN Savings Institutions
- Sector
- VTYX Health Care
- BFIN Finance
- Exchange
- VTYX Nasdaq
- BFIN Nasdaq
- Market Cap
- VTYX 154.9M
- BFIN 153.0M
- IPO Year
- VTYX 2021
- BFIN N/A
- Fundamental
- Price
- VTYX $1.70
- BFIN $12.04
- Analyst Decision
- VTYX Buy
- BFIN
- Analyst Count
- VTYX 4
- BFIN 0
- Target Price
- VTYX $11.33
- BFIN N/A
- AVG Volume (30 Days)
- VTYX 1.5M
- BFIN 18.1K
- Earning Date
- VTYX 05-08-2025
- BFIN 07-30-2025
- Dividend Yield
- VTYX N/A
- BFIN 3.32%
- EPS Growth
- VTYX N/A
- BFIN N/A
- EPS
- VTYX N/A
- BFIN 0.36
- Revenue
- VTYX N/A
- BFIN $48,547,000.00
- Revenue This Year
- VTYX N/A
- BFIN $1.43
- Revenue Next Year
- VTYX N/A
- BFIN $4.33
- P/E Ratio
- VTYX N/A
- BFIN $33.76
- Revenue Growth
- VTYX N/A
- BFIN N/A
- 52 Week Low
- VTYX $0.78
- BFIN $9.71
- 52 Week High
- VTYX $5.66
- BFIN $13.97
- Technical
- Relative Strength Index (RSI)
- VTYX 61.97
- BFIN 47.40
- Support Level
- VTYX $1.68
- BFIN $11.86
- Resistance Level
- VTYX $1.85
- BFIN $12.22
- Average True Range (ATR)
- VTYX 0.15
- BFIN 0.26
- MACD
- VTYX 0.04
- BFIN 0.01
- Stochastic Oscillator
- VTYX 67.05
- BFIN 33.33
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About BFIN BankFinancial Corporation
BankFinancial Corp is a full-service, national bank providing banking, financial planning and fiduciary services to individuals, families and businesses in the Chicago metropolitan area and on a regional or national basis for commercial finance, healthcare finance, equipment finance, commercial real estate finance and treasury management business customers. The Bank offers its customers a broad range of loan, deposit, trust and other financial products and services through approximately 18 full-service banking offices located in Cook, DuPage, Lake and Will Counties, Illinois and through its Internet Branch.